Bepridil is potent against SARS-CoV-2 in vitro
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Guided by a computational docking analysis, we experimentally characterized about 30 FDA/EMA-approved drugs on their inhibition of essential main protease of SARS-CoV-2, the pathogen of COVID-19. From this study, we discovered that bepridil, an antianginal medication, is potent against SARS-CoV-2. The antiviral analysis of bepridil indicated that it had low micromolar EC 50 values in inhibiting SARS-CoV-2 in two highly permissive mammalian cell lines. Due to the urgent matter of COVID-19, our current study encourages further preclinical investigations of bepridil in animal models to clear its path for clinical uses in COVID-19 patients.
Article activity feed
-
-
-
SciScore for 10.1101/2020.05.23.112235: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources SARS-CoV-2 inhibition by a cell-based assay: A slightly modified standard live virus-based microneutralization (MN) assay was used as previously described(40-42) to rapidly evaluate the drug efficacy against SARS-CoV-2 infection in Vero E6 and A549 cell cultures. Vero E6suggested: NoneThe toxicity to the treated cells was assessed by observing floating cells and altered morphology of adhered Vero E6 and A549 cells in wells under the … SciScore for 10.1101/2020.05.23.112235: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources SARS-CoV-2 inhibition by a cell-based assay: A slightly modified standard live virus-based microneutralization (MN) assay was used as previously described(40-42) to rapidly evaluate the drug efficacy against SARS-CoV-2 infection in Vero E6 and A549 cell cultures. Vero E6suggested: NoneThe toxicity to the treated cells was assessed by observing floating cells and altered morphology of adhered Vero E6 and A549 cells in wells under the microcopy. A549suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)Software and Algorithms Sentences Resources We used GraphPad 8.0 to analyze the data and used the [Inhibitor] vs. response - Variable slope (four parameters) fitting to determine the values of both IC50 and Hill coefficient. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-